| Summary: | 碩士 === 高雄醫學大學 === 生物醫學暨環境生物學研究所 === 101 === Food and Drug Administration (FDA, U.S.A.) has approved the PEGylated technology that can use in clinical treatment. With the times, numbers of PEGylated molecule has entered to clinical use, such as protein, liposome and small molecule. In previous study, we have established an anti-PEG sandwich ELISA (AGP4/3-3-Biotin) that can quantify the pegylated compounds. However, the sensitivity of this PEG quantification platform might be affected that depend on the different kind of the pegylated molecules. In this study, we established an anti-PEG sandwich ELISA according to the different combination of the high affinity anti-PEG antibodies that can extensive quantification to any kind of pegylated compound. We also established the cell line (293T/anti-PEG) that can anchor the anti-PEG antibody on mammalian cell membrane. These high affinity anti-PEG antibodies and the anti-PEG cell line can be used in sandwich ELISA to quantify pegylated molecules. These anti-PEG sandwich ELISA provide a high sensitive, convenient and inexpensive tool to the pharmacokinetic studies of PEGylated molecules.
|
|---|
